Bayer Loses Bid to Demand Royalties From Abbott on Humira Drug

Bayer AG, Europe’s largest drug and chemical maker, lost its bid to demand royalties from Abbott Laboratories over U.S. sales of the arthritis drug Humira.

Bayer, which sued Abbott in 2008 for violating its intellectual-property rights, conceded in a court filing yesterday that Humira doesn’t infringe its patent under an interpretation by a judge in the case. Bayer’s lawsuit can be revived if an appeals court overturns the judge’s definition of the phrase “human monoclonal antibodies.”